Shares of Soligenix have experienced a notable surge following the successful trial of the company’s vaccine candidate, which has demonstrated protection against two dangerous viruses.
Impressive Performance
As of midday trading, the stock has soared by a remarkable 19%, reaching 90 cents. This recent surge marks a significant achievement for Soligenix, as its shares have risen by over 50% in the past three months.
Advancements in Vaccine Development
Headquartered in Princeton, N.J., Soligenix is an esteemed biopharmaceutical company specializing in the development of treatments for rare diseases. The company has published an encouraging preclinical efficacy study on their single-vial thermostabilized bivalent vaccine. The study revealed that this innovative vaccine provided full protection against Sudan ebolavirus and Marbug marburgvirus.
Addressing Unmet Medical Needs
It is vital to note that there are currently no approved vaccines or treatments available for Sudan ebolavirus or Marbug marburgvirus. Therefore, Soligenix’s vaccine candidate represents a groundbreaking step towards combatting these dangerous viruses.
Enhanced Stability
In addition to its remarkable efficacy, the candidate vaccine has also demonstrated commendable stability. Previous studies have shown that it remains stable even when exposed to temperatures of up to 104 degrees Fahrenheit for at least two years.
Collaboration with University of Hawaii at Manoa
The significant findings included in this manuscript were made possible through a collaborative effort between Soligenix and the esteemed University of Hawaii at Manoa. Their joint research has been published in the prestigious scientific journal Vaccine.
Continued advancements in Soligenix’s vaccine candidate provide hope for the future treatment of these deadly viruses.